Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Epidemiology and Global Trends in COVID-19 Vaccines
share announcement

Epidemiology and Global Trends in COVID-19 Vaccines

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 7895

Special Issue Editor

Dr. Muhammad Atif Zahoor

E-Mail Website
Guest Editor
Viral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C, Canada
Interests: host-virus interactions; innate immunity; cell signaling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is responsible for the current pandemic and has had a deleterious impact on public health and the global economy. As of Dec 27, 2021, there have been 279 million confirmed cases of COVID-19, including 5.39 million deaths. With no other obvious short-term resolution, mRNA vaccines, recombinant protein vaccines, inactivated vaccines, viral vector-based vaccines, and DNA vaccines seem to be a key strategy to combat COVID-19 around the world. Although, unprecedented in human history, the vaccine-driven relief of the pandemic is expected, the emerging variants are raising concerns about breakthrough infections. These emerging variants will not only keep the host immunity under constant pressure but also render the efficacy of vaccine candidates uncertain. Thus, to overcome this evolving SARS-CoV-2 menace, evolving vaccines and vaccine strategies are required. To that end, this Special Issue will address the current epidemiology and spread of COVID-19 as well as its prevention through effective vaccines.

Dr. Muhammad Atif Zahoor
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • advances in vaccines
  • vaccine development
  • vaccine formulations or technologies
  • animal models describing protection against COVID-19

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

21 pages, 293 KiB  
Review
SARS-CoV-2 Vaccination and the Bridge between First and Fourth Dose: Where Are We?
by Cristina Stasi, Barbara Meoni, Fabio Voller and Caterina Silvestri
Vaccines 2022, 10(3), 444; https://doi.org/10.3390/vaccines10030444 - 14 Mar 2022
Cited by 13 | Viewed by 7295
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has induced the explosion of vaccine research. Currently, according to the data of the World Health Organization, there are several vaccines in clinical (145) and preclinical (195) stages, while at least 10 are already [...] Read more.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has induced the explosion of vaccine research. Currently, according to the data of the World Health Organization, there are several vaccines in clinical (145) and preclinical (195) stages, while at least 10 are already in clinical phase 4 (post-marketing). Vaccines have proven to be safe, effective, and able to reduce the spread of SARS-CoV-2 infection and its variants, as well as the clinical consequences of the development of coronavirus disease-19 (COVID-19). In the two-dose primary vaccination, different time intervals between the two doses have been used. Recently, special attention has been paid to assessing the immunogenicity following booster administration. The third dose of the vaccine against COVID-19 may be administered at least 8 weeks after the second dose. In Israel, a fourth dose has already been approved in immunocompromised groups. The main objective of this review is to describe the principal results of studies on the effectiveness of first-to-fourth dose vaccination to reduce reinfection by variants and the incidence of severe disease/death caused by COVID-19. Vaccines have shown a high level of protection from symptomatic infection and reinfection by variants after a third dose. Accelerating mass third-dose vaccination could potentially induce immunogenicity against variants. Full article
(This article belongs to the Special Issue Epidemiology and Global Trends in COVID-19 Vaccines)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop